EP0080283B1 - Tripeptides contenant la N-carboxyalcoylproline - Google Patents

Tripeptides contenant la N-carboxyalcoylproline Download PDF

Info

Publication number
EP0080283B1
EP0080283B1 EP82305879A EP82305879A EP0080283B1 EP 0080283 B1 EP0080283 B1 EP 0080283B1 EP 82305879 A EP82305879 A EP 82305879A EP 82305879 A EP82305879 A EP 82305879A EP 0080283 B1 EP0080283 B1 EP 0080283B1
Authority
EP
European Patent Office
Prior art keywords
proline
compound according
alanyl
prolyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP82305879A
Other languages
German (de)
English (en)
Other versions
EP0080283A1 (fr
Inventor
Francis Richard Pfeiffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to AT82305879T priority Critical patent/ATE17736T1/de
Publication of EP0080283A1 publication Critical patent/EP0080283A1/fr
Application granted granted Critical
Publication of EP0080283B1 publication Critical patent/EP0080283B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This compound (24.2 g, 0.0096 m) was condensed with 2.25 g (0.0072 m) of L-alanyl-L-proline, benzyl ester hydrochloride in the dicyclohexylcarbodiimide procedure to give 0.8 g of N-(2-carbethoxy)ethyl-L-propyl-alanyl-L-proline, benzyl ester.
  • the pro-drug precursor was hydrolyzed with barium hydroxide in aqueous methanol to give 0.498 g (64%) of N-(2-carboxyethyl)-L-prolyl-L-alanyl-L-proline, m.p. 133-136°.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (13)

1. Un procédé pour 1 préparation d'un tripeptide de la formule structurelle:
Figure imgb0021
dans laquelle:
R est carboxy, sulfo ou phosphono;
alk est une chaîne alcoylène droite ou ramifiée de 1-5 carbones qui n'est pas éthylidène;
X est O ou H, H;
Y est H et peut aussi être -OH lorsque X est H, H; et lorsque X et Y sont H, H et H respectivement, ----- est facultativement un lien carbone-carbone;
n est un nombre entier de 0-3 inclusivement; et
A est un résidu d'acide amino dérivé de D- ou L-Ala, D- ou L-Phe, D- ou L-béta-méthyl-béta-Ala, D- ou L-phényl-Gly, D- ou L-béta-phényl-béta-Ala, D- ou L-béta-thiényl-Gly, D- ou L-béta-Ala, y-acide aminobutyrique; D- ou L-2-acide aminobutyrique, D- ou L-nor-Val, D- ou L-nor-Leu, 3-amino-3-acide butyriqueméthyle, 2-méthyl-Ala ou un dérivé de N-méthyle desdits résidus; ou un sel pharmaceutiquement acceptable ou un dérivé pro-médicament du dit composé; comprenant la réaction d'un composé de la formule structurelle:
Figure imgb0022
avec un composé de la formule structurelle:
Figure imgb0023
dans laquelle A, X, Y, -----, alk et n sont comme définis plus haut, R1 est carboxy protégé, sulfo ou phosphono; R2 est un groupe protecteur carboxy; et R3 est le groupe amino ou N-méthylamino qui fait partie de A comme défini plus haut; l'évacuation de tous groupes protecteurs et la formation facultative d'un sel pharmaceutiquement acceptable ou d'un dérivé promédicament.
2. Un procédé selon la revendication 1 dans laquelle la réaction est effectuée en présence d'un carbodiimide.
3. Un procédé selon la revendication 1 dans laquelle la réaction est effectuée en présence d'un dicyclohexylcarbodii mide.
4. Un procédé selon la revendication 1 dans laquelle béta-alanyl-L-proline en tant que chlorhydrate d'ester de benzyl est mis en réaction avec le chlorhydrate de N-carbométhoxyméthyl-L-proline pour produire N-carboxyméthyl-L-prolyl-béta-alanyl-L-proline.
5. Un procédé pour la préparation d'une composition pharmaceutique qui consiste à ajouter tout en mélangeant un tripeptide, comme défini dans la revendication 1, avec un support pharmaceutiquement acceptable.
EP82305879A 1981-11-06 1982-11-05 Tripeptides contenant la N-carboxyalcoylproline Expired EP0080283B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT82305879T ATE17736T1 (de) 1981-11-06 1982-11-05 N-carboxyalkylprolin-enthaltende tripeptide.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31872181A 1981-11-06 1981-11-06
US318721 1981-11-06

Publications (2)

Publication Number Publication Date
EP0080283A1 EP0080283A1 (fr) 1983-06-01
EP0080283B1 true EP0080283B1 (fr) 1986-01-29

Family

ID=23239338

Family Applications (1)

Application Number Title Priority Date Filing Date
EP82305879A Expired EP0080283B1 (fr) 1981-11-06 1982-11-05 Tripeptides contenant la N-carboxyalcoylproline

Country Status (25)

Country Link
EP (1) EP0080283B1 (fr)
JP (1) JPS5890537A (fr)
KR (1) KR880002594B1 (fr)
AT (1) ATE17736T1 (fr)
AU (1) AU562011B2 (fr)
CA (1) CA1247085A (fr)
CS (1) CS235030B2 (fr)
DD (1) DD206553A5 (fr)
DE (1) DE3268884D1 (fr)
DK (1) DK480682A (fr)
ES (1) ES517144A0 (fr)
FI (1) FI75175C (fr)
GR (1) GR77368B (fr)
HU (1) HU187808B (fr)
IE (1) IE53982B1 (fr)
IL (1) IL67070A (fr)
NO (1) NO160081C (fr)
NZ (1) NZ202232A (fr)
PH (1) PH18708A (fr)
PL (1) PL136098B1 (fr)
PT (1) PT75769B (fr)
RO (1) RO84706B (fr)
YU (1) YU245582A (fr)
ZA (1) ZA827816B (fr)
ZW (1) ZW23282A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0500989B1 (fr) * 1991-02-27 1998-12-09 Lacer, S.A. Agents antihypertensifs dipeptidiques N-(pyridyl-alpha-substituée) carbonyle
CA2223625C (fr) 1995-06-06 2003-06-03 Pfizer Inc. (indole-2-carbonyl-)-amides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
KR100241643B1 (ko) 1995-06-06 2000-03-02 디. 제이. 우드 당뇨병치료제인 치환된 N-(인돌-2-카르보닐)-β-알라님아미드 및 그의 유도체
CA2224062C (fr) * 1995-06-06 2001-09-04 Pfizer Limited (indole-2-carbonyl-)-glycinamides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
US6277877B1 (en) 2000-08-15 2001-08-21 Pfizer, Inc. Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors
KR20040013679A (ko) * 2002-08-08 2004-02-14 현대산업개발 주식회사 실내 공기 상태 표시장치

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique

Also Published As

Publication number Publication date
GR77368B (fr) 1984-09-11
FI75175B (fi) 1988-01-29
HU187808B (en) 1986-02-28
DD206553A5 (de) 1984-02-01
IL67070A0 (en) 1983-02-23
JPS5890537A (ja) 1983-05-30
IE53982B1 (en) 1989-05-10
ES8401447A1 (es) 1983-12-16
FI75175C (fi) 1988-05-09
YU245582A (en) 1985-03-20
PL238893A1 (en) 1983-07-04
NZ202232A (en) 1985-08-16
FI823798A0 (fi) 1982-11-05
IE822647L (en) 1983-05-06
ATE17736T1 (de) 1986-02-15
EP0080283A1 (fr) 1983-06-01
KR880002594B1 (ko) 1988-12-03
CA1247085A (fr) 1988-12-20
NO160081B (no) 1988-11-28
FI823798L (fi) 1983-05-07
PT75769B (en) 1985-07-26
DK480682A (da) 1983-05-07
IL67070A (en) 1986-01-31
AU9017382A (en) 1983-05-12
NO160081C (no) 1989-03-08
RO84706B (ro) 1984-09-30
ZA827816B (en) 1983-08-31
DE3268884D1 (en) 1986-03-13
PH18708A (en) 1985-09-05
CS235030B2 (en) 1985-04-16
ES517144A0 (es) 1983-12-16
KR840002372A (ko) 1984-06-25
ZW23282A1 (en) 1983-02-23
NO823693L (no) 1983-05-09
PT75769A (en) 1982-11-01
AU562011B2 (en) 1987-05-28
PL136098B1 (en) 1986-01-31
RO84706A (fr) 1984-07-17

Similar Documents

Publication Publication Date Title
KR850001269B1 (ko) 아미노산 유도체의 제조방범
KR900002560B1 (ko) 신규 펩티드 화합물의 제법
IE62334B1 (en) Phosphinic acid derivatives
JPH0346463B2 (fr)
NZ200164A (en) N-substituted amido-amino acids and pharmaceutical compositions
PT90659B (pt) Processo para a preparacao de inibidores de renina contendo diois
US4216209A (en) Tripeptide angiotensin converting enzyme inhibitors
EP0074787B1 (fr) Dipeptides actifs sur les reins
JPH01157998A (ja) Ｌ−プロリン誘導体及びその製造方法並びにそれを含有する医薬組生物
HU182866B (en) Process for preparing new tetrapeptide derivatives
EP0080283B1 (fr) Tripeptides contenant la N-carboxyalcoylproline
US4456594A (en) N-Carboxyalkylproline-containing tripeptides
EP0103496A1 (fr) Dérivés aminés et iminés d'acides acylalkylamino-carbonyl substitués
GB2086912A (en) Enkephalin derivatives production thereof and pharmaceutical compositions
CA1059994A (fr) Derives de l'histidine
EP0136720B1 (fr) Analogues d'encéphaline
US4387049A (en) Adamantyl containing peptides
US4474767A (en) Peptide and pseudopeptide derivatives
EP0159396B1 (fr) Dérivés carboxyalkyl peptides
US4400511A (en) 2-Substituted octahydropyrrolo(1,2-A)-pyrazine-3-carboxylic acids
JPH0330599B2 (fr)
EP0058567A1 (fr) Dérivés acyliques substitués des acides octahydro-1H-isoindole-1-carboxyliques et de ses esters
US4172130A (en) α-AMINOACYL CONTAINING NEW PEPTIDES WITH GASTRIN EFFECTS AND A PROCESS FOR THE PREPARATION THEREOF
EP0086660B1 (fr) Tétrapeptides actifs dans les reins
US4386075A (en) Renally active tetrapeptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19821112

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

ITF It: translation for a ep patent filed

Owner name: JACOBACCI & PERANI S.P.A.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 17736

Country of ref document: AT

Date of ref document: 19860215

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3268884

Country of ref document: DE

Date of ref document: 19860313

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19861130

26N No opposition filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19891003

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19891027

Year of fee payment: 8

Ref country code: AT

Payment date: 19891027

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19891031

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19891122

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19891127

Year of fee payment: 8

ITTA It: last paid annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19891130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19891130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19891130

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19900201

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19901105

Ref country code: AT

Effective date: 19901105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19901106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19901130

BERE Be: lapsed

Owner name: SMITHKLINE BECKMAN CORP.

Effective date: 19901130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19910601

GBPC Gb: european patent ceased through non-payment of renewal fee
NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19910731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19910801

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 82305879.7

Effective date: 19910705